Recent studies suggest that microbeads composed of green tea, vitamin E, and seaweed could provide new avenues for weight loss, potentially offering alternatives to GLP-1 drugs and bariatric surgery.
While human testing is still needed, researchers in China observed that rats on high-fat diets lost approximately 17% of their body weight when they consumed these dietary microbeads. The rats also experienced reduced blood fat levels compared to their counterparts that didn’t receive the beads, alongside diminished liver damage.
A researcher from Sichuan University, who contributed to the study published in the Journal Cell Biomaterials, noted, “Our work lays the groundwork for innovative dietary strategies to address obesity.”
With obesity affecting nearly 890 million adults globally, it’s highlighted as a significant health crisis. The study points out that excessive dietary fat is a major factor contributing to conditions like type 2 diabetes, cardiovascular illness, and certain cancers. Thus, mitigating fat intake is seen as a promising strategy.
Yueu, another co-author of the research, highlighted in a statement from the American Chemical Society (ACS) that “Weight loss can aid in preventing long-term health issues like diabetes and heart disease.” The microbeads, according to her, work by blocking fat absorption in a gentle, non-invasive way while being designed to align with typical eating habits.
The findings were presented at the ACS Fall digital meeting held in August. The unique coating of these beads, derived from seaweed, effectively shields them from stomach acid.
The microbeads are formulated from green tea polyphenols—antioxidants sourced from tea leaves—combined with vitamin E, which binds to fat droplets in the intestines, effectively preventing their absorption. ACS reports that these nearly tasteless beads can be incorporated into everyday foods, even being utilized in tapioca-like bowls for desserts or bubble tea.
In a month-long study where the dietary rat group consumed a diet comprising 60% fat, there were no noticeable side effects or variations in their blood glucose after taking the microbeads. The beads showed similar fat excretion levels compared to Orlistat, an FDA-approved fat blocker, but avoided the gastrointestinal troubles commonly associated with it.
Orlistat can lead to digestive issues as unabsorbed fat passes through the colon. In contrast, the experimental microbeads appear to inhibit both fat and weight gain without disrupting blood sugar, digestive efficiency, or energy levels.
While observing the effects of semaglutide—the active ingredient in medications like Ozempic and Wegovy—on rats, researchers noted it lowered blood sugar but also triggered fluctuations that could lead to lethargy, raising concerns about potential side effects in further animal studies.
The study emphasized the need for more research to evaluate long-term safety, efficacy, and potential clinical applications. The scientists stated that their findings present a foundational concept for obesity treatment using PMFL microbeads but caution that more thorough investigation is warranted.
All components of the microbeads are deemed safe for food use and are FDA-approved, though the microbead formulation itself awaits regulatory review. Biotechnology firms are collaborating with researchers to expand manufacturing capabilities, with human clinical trials beginning in China soon. Early results are anticipated within a year.
